Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.

Trial Profile

Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar disorders; Schizophrenia
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 15 Jul 2011 New trial record
    • 01 Jun 2011 Results published in the Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top